SYNOPSIS

Treatment response and residual-disease monitoring in initial and relapsed TEL-AML1 positive childhood ALL
In recently reported studies, the analyses of residual leukemic cells by sensitive and specific molecular methods or flowcytometric techniques during multi-agent chemotherapy in childhood ALL provide measurable evidence on the effectiveness of therapy. 1, 2 Furthermore, the detection of minimal residual disease (MRD) after induction of remission has been shown to be of significant prognostic value, thus permitting the stratification of children with ALL to less toxic or more intensive treatment arms. 1 In the majority of ALL, clonal rearrangements of the T-cell receptor (TCR) and immunoglobulin (Ig) gene loci represent unique clone-specific marker for MRD monitoring. However, this DNA-based approach is burdened both with high costs, and time and labor intensity. The detection of fusion transcripts by reverse transcriptasepolymerase chain reaction (RT-PCR) represents an alternative molecular surveillance method in 35-45% of childhood ALL. 3 The TEL-AML1 fusion transcript [t(12;21)(p13;q22)] represents the most common genetic rearrangement in childhood ALL and is detected in 20 to 25% of initial ALL. Both at initial manifestation and at relapse, TEL-AML1 + ALL are characterized by their confinement to B cell precursor ALL, mostly leukocyte counts Ͻ50 × 10 9 /l, age between 2 and 10 years, [4] [5] [6] a nonhyperdiploidy, and in the event of a relapse by a long duration of remission (median 46 months). 6, 7 Another characteristic of TEL-AML1 + ALL is its association with an excellent prognosis and short-term outcome on current intensive multiagent therapeutic regimens. This observation is currently in discussion since assessment of TEL-AML1 positivity in relapsed childhood ALL has revealed a wide range of prevalences (3.1%-28%) either supporting or contradicting its positive prognostic feature. [8] [9] [10] Although an effect of frontline therapeutic regimens can not be ruled out, these discrepancies are in part due to retrospective study design, low sample numbers and the lack of consideration of the long duration of remission of TEL-AML1 + ALL. Nonetheless, the TEL-AML1 + group is non-uniform and the identification of distinguishing features is required in order to stratify patients reliably to treatment arms. This molecular study analyzes response to therapy of initial and relapsed childhood TEL-AML1 + ALL during early phases of induction, assesses residual leukemia in follow-up samples, and aims at identifying children in hematologic remission with the highest risk of relapse.
Three analyses was performed prospectively. Written informed consent was obtained from the patients or their guardians. The ALL-BFM studies and ALL-REZ BFM studies were approved by the Institutional Review Boards of the Medical School Hannover and the Freie Universität Berlin and Humboldt-University at Berlin, respectively.
Mononuclear cells were obtained after centrifugation on a Ficoll-Hypaque gradient. RNA isolation and reverse transcription have been described elsewhere. 6, 7 The quality and quantity of RNA was assessed on an ethidium bromide-stained 1% agarose gel. Nested PCR of TEL-AML1 cDNA were performed as published previously. [5] [6] [7] The integrity of the isolated RNA, the correctness of the cDNA synthesis and the PCR was checked by separate amplification of the ubiquitously expressed ABL mRNA. Amplification of TEL-AML1 and ABL cDNA was carried out under the same PCR conditions as previously described. 6, 7 Each run of PCR analysis included a TEL-AML1 + sample (eg REH B cell precursor ALL cell line) and no template cDNA as negative control. For MRD testing, meticulous precautions were undertaken to prevent false positive results. Each analysis was confirmed independently. To consider a result valid, a readily visible ABL and REH PCR product had to be present in the control PCR, and each negative control had to be negative.
Total RNA from 2 × 10 6 leukemic cells was reverse transcribed and one quarter of the RT product was used in the first-round PCR. At the end, 2 l of a 1:100 dilution of the first-round PCR product are subjected to a second-round of PCR. Serial dilution experiments established that the nested RT-PCR assay allows the detection of one TEL-AML1 + cell in the background of /l). Longitudinal follow-up examinations could be performed on 184 BM samples from 94 children with initial TEL-AML1 + ALL at diagnosis (day 0), during induction (days 15 and 33) and before reintensification (day 148). All of the children achieved a hematological complete response after induction. Molecular analyses showed a conversion to PCR negativity in approximately 35% of the tested patients at the first time-point (day 15) and in 78% after induction (day 33) (Figure 1 ). After consolidation, 6% (3/51) of the patients were still molecular TEL-AML1 positive. Once molecular negativity was achieved, subsequent controls performed at later diagnostic time-points remained negative.
During the clinical follow-up, two out of 20 children (10%) with detectable residual disease at the end of induction therapy have relapsed (11 and 57.8 months after diagnosis), in contrast to none of the 70 patients with molecular conversion (P = 0.0074). The child with the very short remission duration (11 months) presented with high-risk features (leukocytosis, poor prednisone response) and was transplanted in first complete remission. After relapsing shortly after transplant, the patient is now 11 months in CCR after second transplant. The second child had an extramedullary relapse, and is presently 9 months in remission during ALL-REZ BFM 96 relapse therapy. The three patients with TEL-AML1 positivity after consolidation are in CR at 12.5, 21, and 36 months. The relapse trial ALL-REZ BFM consists of alternating courses of chemotherapy given in approximately 3-week intervals. Eighty follow-up BM samples were analyzed sequentially in 37 children with relapsed TEL-AML1 + ALL at diagnosis and before courses 2-5 (days 21, 42, 63 and 84). The majority of the children with relapsed TEL-AML1 + ALL (30/37) had a late relapse (Ͼ30 months after initial diagnosis). Based on cytology, a hematological remission was achieved in 8/31 (25.8%) of the children before the second treatment course (day 21) and in all of the children tested before the third course (day 42) of the ALL-REZ BFM relapse trials. Molecular analyses of TEL-AML1 status on BM samples performed at the same time-points revealed residual leukemia in 17/27 (63%) and 9/26 (34.6%), respectively (see Figure 1) . A molecular remission was not achieved in 4/14 (29%) and 3/10 Among the nine patients being tested persistently TEL-AML1 positive before third course (day 42), six were treated by chemotherapy only, and three received an allogeneic BMT. Four of the six patients (66%) of the chemotherapy group have relapsed at 6, 26, 47, and 61 months, and two are in remission at 5 and 35 months. In the BMT group, 2/3 children have relapsed. In contrast, among the 17 patients tested TEL-AML1 negative on day 42, 14 received chemotherapy only, and three had an allogeneic BMT. Only two (14%) of the chemotherapy group have relapsed at 30 and 36 months, as well as two of the transplanted group (P = 0.037).
This combined molecular genetic study of three diagnostic centers provided the opportunity to evaluate and compare the response to therapy and the predictive value of MRD detection by nested PCR amplification of chimeric TEL-AML1 cDNA in a large cohort of children with TEL-AML1 + ALL at initial diagnosis and at relapse treated uniformly according to ALL frontline or relapse trials of the BFM study group. Four smaller studies on TEL-AML1 + ALL have addressed the potential utility of conventional nested or real-time RT-PCR for the analysis of MRD. 10, 13 Serial follow-up times were, however, too limited to correlate results with outcome. In our study, despite morphological remission, 22.2% of initial ALL are molecular late responders with persistent TEL-AML1 positivity after induction therapy (day 33). Two of 20 patients have subsequently relapsed in contrast to none of the 70 TEL-AML1 MRD negative patients (P Ͻ 0.01). Accordingly, patients being molecular positive for the TEL-AML1 fusion after induction could be regarded as being at increased risk of relapse. This consideration on increased risk of relapse might be even more relevant for children remaining persistently positive even after consolidation therapy, although in this study these patients are presently in first CR. As mentioned before, final judgment of outcome, especially in this ALL subgroup, requires longer follow-up times. Nevertheless, supporting this assumption are the findings of the semiquantitative DNA-based MRD study on initial ALL showing that patients with a high degree of MRD after consolidation have a three-to nine-fold higher risk of relapse. 1, 2 Initial molecular response of children with newly diagnosed or relapsed TEL-AML1 + ALL evaluated at corresponding timepoints of treatment was in the same range at the first diagnostic time point (63-65%; day 15 vs day 21). However, in comparison to initial disease, a higher proportion of children with relapsed TEL-AML1 + ALL remained persistently molecular TEL-AML1 positive in subsequent analyses (Figure 1 ) possibly indicating a higher degree of resistance of leukemic cells at relapse (22.2% (day 33) vs 34.6% (day 42)) and accordingly a higher risk of relapse.
In the BFM studies, the prevalence of TEL-AML1 + BCP-ALL at relapse is approximately 17% in prospective analyses. 9 This amount is similar to the proportion of children with TEL-AML1 positivity after induction therapy of initial ALL. However, whether this approach addresses the crucial issue of risk of relapse and early relapse detection correctly is handicapped by the long duration of remission inherent to TEL-AML1 + ALL requiring longer follow-up times. Generally, these reflections should be taken into consideration in all clinical studies addressing the prognostic value of detection of MRD. Therapeutic decisions concerning reduction, intensification or prolongation of therapy for this molecularly defined ALL subset warrants international comparison with other therapeutic trials.
In conclusion, in approximately 20% of initial and relapsed childhood ALL, the sensitive and rapid assessment of the kinetics of leukemic cell reduction during induction therapy and in morphological remission by nested RT-PCR of leukemiaspecific TEL-AML1 fusion transcripts allows a distinction among TEL-AML1 positive ALL. The fast reduction of TEL-AML1 positive blast cells in a majority of children with initial or relapsed TEL-AML1 + ALL below the detection limit of nested RT-PCR seems to be a prerequisite for long-term CR, allowing a better determination of relapse risk and a more appropriate treatment stratification.
